Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Adaptimmune Therapeutics PLC Corporate Call Transcript

Sep 09, 2022 / 12:00PM GMT
Release Date Price: $1.92 (-5.88%)
Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Good morning. I'm Adrian Rawcliffe, Adaptimmune's CEO, and thank you for joining us. I refer you to our disclaimer. More details can be found in the press release we issued earlier this morning. I'm delighted to be introducing this new data from our SURPASS trial and our plans for the SURPASS family of trials. This data set confirms the power of our SPEAR T-cells to make a difference for patients. It identifies multiple tumor types for further development, and it continues our leadership position making T cells effective against solid tumors.

But before we get into that, I want to provide a little background on Adaptimmune and our technology. For those of you who are perhaps less familiar with Adaptimmune, we engineer T cells to fight cancer, empowering a person's own immune system against their disease. Our unique technology platform enables us to enhance the affinity of T cell receptors, or TCRs. T cells use TCRs to see targets on cells. If a target is recognized as alien, the T cell will kill

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot